Cargando…

Identification of second malignancies on effusions and fine-needle aspirates using a panel of monoclonal antibodies.

The longer survival of neoplastic patients achieved through improvements of therapeutic regimens has increased the relative risk of developing a second primary tumour (SPT). In this context, conventional cytopathology can define tumour histotype only in a small fraction of cases. In this study, we h...

Descripción completa

Detalles Bibliográficos
Autores principales: Mottolese, M., Venturo, I., Rinaldi, M., Lopez, M., Bigotti, G., Benevolo, M., Natali, P. G.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group|1 1997
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063306/
https://www.ncbi.nlm.nih.gov/pubmed/9052413
_version_ 1782137308807430144
author Mottolese, M.
Venturo, I.
Rinaldi, M.
Lopez, M.
Bigotti, G.
Benevolo, M.
Natali, P. G.
author_facet Mottolese, M.
Venturo, I.
Rinaldi, M.
Lopez, M.
Bigotti, G.
Benevolo, M.
Natali, P. G.
author_sort Mottolese, M.
collection PubMed
description The longer survival of neoplastic patients achieved through improvements of therapeutic regimens has increased the relative risk of developing a second primary tumour (SPT). In this context, conventional cytopathology can define tumour histotype only in a small fraction of cases. In this study, we have evaluated whether selected combinations of monoclonal antibodies (MAbs) to tumour-associated antigens (TAAs) can increase the accuracy of conventional morphology in detecting second primary tumours (SPTs) in two particularly difficult areas of cytodiagnosis, namely that of effusions and pulmonary fine-needle aspirates (FNAs). The immunocytochemical (ICC) analysis of 334 cytological specimens demonstrated that the use of our selected panel of MAbs could allow a more efficient identification of SPTs in comparison with conventional morphology. This diagnostic improvement was statistically significant (P < 0.0001). The present findings show that the immunophenotyping of effusions and FNAs, providing a more accurate and objective identification of SPTs, may have significant therapeutic and epidemiological relevance.
format Text
id pubmed-2063306
institution National Center for Biotechnology Information
language English
publishDate 1997
publisher Nature Publishing Group|1
record_format MEDLINE/PubMed
spelling pubmed-20633062009-09-10 Identification of second malignancies on effusions and fine-needle aspirates using a panel of monoclonal antibodies. Mottolese, M. Venturo, I. Rinaldi, M. Lopez, M. Bigotti, G. Benevolo, M. Natali, P. G. Br J Cancer Research Article The longer survival of neoplastic patients achieved through improvements of therapeutic regimens has increased the relative risk of developing a second primary tumour (SPT). In this context, conventional cytopathology can define tumour histotype only in a small fraction of cases. In this study, we have evaluated whether selected combinations of monoclonal antibodies (MAbs) to tumour-associated antigens (TAAs) can increase the accuracy of conventional morphology in detecting second primary tumours (SPTs) in two particularly difficult areas of cytodiagnosis, namely that of effusions and pulmonary fine-needle aspirates (FNAs). The immunocytochemical (ICC) analysis of 334 cytological specimens demonstrated that the use of our selected panel of MAbs could allow a more efficient identification of SPTs in comparison with conventional morphology. This diagnostic improvement was statistically significant (P < 0.0001). The present findings show that the immunophenotyping of effusions and FNAs, providing a more accurate and objective identification of SPTs, may have significant therapeutic and epidemiological relevance. Nature Publishing Group|1 1997 /pmc/articles/PMC2063306/ /pubmed/9052413 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Mottolese, M.
Venturo, I.
Rinaldi, M.
Lopez, M.
Bigotti, G.
Benevolo, M.
Natali, P. G.
Identification of second malignancies on effusions and fine-needle aspirates using a panel of monoclonal antibodies.
title Identification of second malignancies on effusions and fine-needle aspirates using a panel of monoclonal antibodies.
title_full Identification of second malignancies on effusions and fine-needle aspirates using a panel of monoclonal antibodies.
title_fullStr Identification of second malignancies on effusions and fine-needle aspirates using a panel of monoclonal antibodies.
title_full_unstemmed Identification of second malignancies on effusions and fine-needle aspirates using a panel of monoclonal antibodies.
title_short Identification of second malignancies on effusions and fine-needle aspirates using a panel of monoclonal antibodies.
title_sort identification of second malignancies on effusions and fine-needle aspirates using a panel of monoclonal antibodies.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063306/
https://www.ncbi.nlm.nih.gov/pubmed/9052413
work_keys_str_mv AT mottolesem identificationofsecondmalignanciesoneffusionsandfineneedleaspiratesusingapanelofmonoclonalantibodies
AT venturoi identificationofsecondmalignanciesoneffusionsandfineneedleaspiratesusingapanelofmonoclonalantibodies
AT rinaldim identificationofsecondmalignanciesoneffusionsandfineneedleaspiratesusingapanelofmonoclonalantibodies
AT lopezm identificationofsecondmalignanciesoneffusionsandfineneedleaspiratesusingapanelofmonoclonalantibodies
AT bigottig identificationofsecondmalignanciesoneffusionsandfineneedleaspiratesusingapanelofmonoclonalantibodies
AT benevolom identificationofsecondmalignanciesoneffusionsandfineneedleaspiratesusingapanelofmonoclonalantibodies
AT natalipg identificationofsecondmalignanciesoneffusionsandfineneedleaspiratesusingapanelofmonoclonalantibodies